Drugs / Kumorixilib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07691333 | Jun 2026 → Jan 2028 expected | hormone receptor-positive breast cancer | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kumorixilib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07691333 ↗ |
| Route | Oral | “180 mg orally once daily” NCT07691333 ↗ |